Sarepta Therapeutics to Present New Data From Its Neuromuscular Portfolio at 2024 World Muscle Society Congress
Sarepta Therapeutics (SRPT): Soaring With Successful Therapies and Cash Flow Positivity
Cantor Fitzgerald Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $152
Cantor Fitzgerald Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)
Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
10 Health Care Stocks With Whale Alerts In Today's Session
Express News | Sarepta Therapeutics Inc - Board Now Comprises Nine Directors, Eight Independent
Sarepta Therapeutics Appoints Deirdre Connelly to Its Board of Directors
High Growth Tech Stocks In The United States You Should Know
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Sarepta Therapeutics on Track for Longest Losing Streak Since September 2019 -- Data Talk
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Sarepta Therapeutics (SRPT) Gets a Buy From TD Cowen
Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar
Unveiling 26 Analyst Insights On Sarepta Therapeutics
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics To Present At Morgan Stanley Healthcare Conference; Webcast At 9:15 AM ET
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $181
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Danaher (DHR)
Russell Companies With the Lowest Tax Rates Expected to Generate $1B in 2025 – GS